source
- FDA grants Capricor three-month extension to review DMD cell therapy dataThe U.S. Food and Drug Administration has given Capricor Therapeutics an additional three months to evaluate its Duchenne muscular dystrophy cell therapy after the agency asked for more information…
- Massachusetts biotech startups see funding gap widen as seed rounds shrink and Series A deals surgeA MassBio report shows that mature biotech firms in Massachusetts captured most of the venture capital in the first half of 2026, with nearly $3.5 billion invested, a 25% rise from the same period…